Elevated heparin-induced antibodies are more common in diabetic patients with vascular disease. - Wikidata - awgldk - TriplyDB

Elevated heparin-induced antibodies are more common in diabetic patients with vascular disease.

Elevated heparin-induced antibodies are more common in diabetic patients with vascular disease.

http://www.wikidata.org/entity/Q37615123

about

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

P2860

Q33443580-A3627F1F-94E2-4928-8C23-E4271864B681

P2860

Elevated heparin-induced antibodies are more common in diabetic patients with vascular disease.

http://www.wikidata.org/entity/Q37615123

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Elevated heparin-induced antib ...... atients with vascular disease.

@en

Elevated heparin-induced antib ...... atients with vascular disease.

@nl

type

label

Elevated heparin-induced antib ...... atients with vascular disease.

@en

Elevated heparin-induced antib ...... atients with vascular disease.

@nl

prefLabel

Elevated heparin-induced antib ...... atients with vascular disease.

@en

Elevated heparin-induced antib ...... atients with vascular disease.

@nl

P1433

Q37615123-17AAB08F-9709-4F0C-A5F7-0A4F9EB36A8F

P1476

Q37615123-EBE77AF9-137C-4590-8F05-668502176ED6

P2093

Q37615123-08DDAE07-F7A5-411B-A741-7289E2F360AF

Q37615123-0E89D985-73C2-46B5-A34B-5609B77E4628

Q37615123-173F2480-C6CB-4EA9-8653-AC2E2F0B7903

Q37615123-3CE59FCE-AFB2-4827-80E4-37AA1A99D557

Q37615123-5C1AB763-1C05-4B27-8231-2EBBDFC288F9

Q37615123-6101C91B-EF0A-4C45-A447-B324044F1D76

Q37615123-63E27751-ACF1-4BF8-9670-5AD31D6E3B3D

Q37615123-B0BC4D4E-41B8-4B46-A154-30E7354064CF

Q37615123-E224E2A8-EB7B-4F2F-B33F-A1C82E7C87F9

P2860

Q37615123-11AA9C09-A101-452A-8E28-859CB755DC2F

Q37615123-169C578E-AD7D-4462-9257-C5B848D53FCF

Q37615123-1D41A224-6D91-4BFC-9822-257FD4C9C2EE

Q37615123-3C563F5D-6FD2-4EF7-BE11-9CB45583EF73

Q37615123-4F04401A-8786-4FBA-8889-9C7C3B883A55

Q37615123-51CD6AFD-E4CF-471A-B74F-3EB05B93F23B

Q37615123-5E00E79F-1C7D-4844-8A8E-BB7862783435

Q37615123-6001F016-A70D-40B4-8971-96BE5666B16E

Q37615123-64FE8AB8-B7A5-4E15-80A3-5F63DC72131C

Q37615123-708D9976-A836-427D-87C1-46571A9B3C45

P304

Q37615123-FEDFEBE3-9AF4-4339-BC9F-11EC04440F90

P31

Q37615123-83F6EEB4-ED02-4B79-855C-6EBDF99EC1D6

P356

Q37615123-CB55AFDE-ACD0-48EC-962F-248EAFE9517C

P478

Q37615123-91ACBFAC-2A2E-40B6-B04E-C61A0D6BD081

P50

Q37615123-449F1926-2774-4004-90D5-384E610CE82D

P577

Q37615123-38964F19-DE7D-4BB1-AC45-B1C8618D7EBD

P5875

Q37615123-62D52B07-127F-4509-B26D-76A3450BBB98

P698

Q37615123-6C264376-B47F-4638-8BD1-275B363B21A7

P932

Q37615123-BD95AB41-BE8A-4C16-A221-C8530085782C

P356

P1433

P1476

Elevated heparin-induced antib ...... patients with vascular disease

@en

P2093

Alan B Lumsden

http://www.w3.org/2001/XMLSchema#string

Eric K Peden

http://www.w3.org/2001/XMLSchema#string

Hosam F El-Sayed

http://www.w3.org/2001/XMLSchema#string

Jean Bismuth

http://www.w3.org/2001/XMLSchema#string

Joseph J Naoum

http://www.w3.org/2001/XMLSchema#string

Mark G Davies

http://www.w3.org/2001/XMLSchema#string

Mitul S Patel

http://www.w3.org/2001/XMLSchema#string

Nibal R Chamoun

http://www.w3.org/2001/XMLSchema#string

Tiffany K Street

http://www.w3.org/2001/XMLSchema#string

P2860

The use of lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia during major vascular surgery.

Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up.

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.

The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment.

Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes.

Beyond the platelet count: heparin antibodies as independent risk predictors.

Thrombotic events in patients with antiplatelet factor 4/heparin antibodies.

Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes.

Heparin-induced thrombocytopenia: present and future.

Use of argatroban as a procedural and bridging anticoagulant in a patient undergoing carotid endarterectomy with concomitant atrial fibrillation.

P304

649652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/649652

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261141134

http://www.w3.org/2001/XMLSchema#string

P698

24672719

http://www.w3.org/2001/XMLSchema#string

P932

3941208

http://www.w3.org/2001/XMLSchema#string